id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-4282-0172,FDA,FDA-2025-P-4282,Reference 27 - Large - Violence in first-episode psychosis A systematic review and meta-analysis,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:10Z,,0,0,09000064b91d3d7f
FDA-2025-P-4282-0154,FDA,FDA-2025-P-4282,Reference 9 - Chalasani - Clozapine Impact on Clinical Outcomes and Aggression in Severely Ill Adolescents with Childhood-Onset Schizophrenia,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:18Z,,0,0,09000064b91d3d6d
FDA-2025-P-4282-0160,FDA,FDA-2025-P-4282,Reference 15 - di Giacomo et al - Prescribing Patterns of Psychotropic Drugs and Risk of Violent Behavior,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:36Z,,0,0,09000064b91d3d73
FDA-2025-P-4282-0164,FDA,FDA-2025-P-4282,Reference 19 - Fazel et al - Schizophrenia and Violence Systematic Review and Meta-Analysis,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:49Z,,0,0,09000064b91d3d77
FDA-2025-P-4282-0167,FDA,FDA-2025-P-4282,Reference 22 - Galletly - Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:57Z,,0,0,09000064b91d3d7a
FDA-2025-P-4282-0148,FDA,FDA-2025-P-4282,Reference 4 - Bitter - Effectiveness of Clozapine Olanzapine Quetiapine Risperidone and Haloperidol Monotherapy,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:42:58Z,,0,0,09000064b91d0f90
FDA-2025-P-4282-0151,FDA,FDA-2025-P-4282,Reference 7 - Cavaliere - Anti-Aggressive Effects of Clozapine in Involuntarily Committed Black Patients with Severe Mental Illness,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:09Z,,0,0,09000064b91d0f93
FDA-2025-P-4282-0178,FDA,FDA-2025-P-4282,Reference 33 - Sariaslan - Associations between individual antipsychotics and the Risk of Arrests and Convictions of Violent and Other Crime,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:30Z,,0,0,09000064b91d3d85
FDA-2025-P-4282-0150,FDA,FDA-2025-P-4282,Reference 6 - Buckley - Violence and Schizophrenia Clozapine as a Specific Antiaggressive Agent,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:05Z,,0,0,09000064b91d0f92
FDA-2025-P-4282-0156,FDA,FDA-2025-P-4282,Reference 11 - Citrome - Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:24Z,,0,0,09000064b91d3d6f
FDA-2025-P-4282-0158,FDA,FDA-2025-P-4282,Reference 13 - de Domenico - The effect of clozapine of aggressive behaviour in patients with chronic schizophrenia,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:30Z,,0,0,09000064b91d3d71
FDA-2025-P-4282-0169,FDA,FDA-2025-P-4282,Reference 24 - Herman - Clinical Response to Clozapine Treatment of 11 Chronic Patients in a State Psychiatric Hospital,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:02Z,,0,0,09000064b91d3d7c
FDA-2025-P-4282-0155,FDA,FDA-2025-P-4282,Reference 10 - Chiles - Effects of Clozapine on Use of Seclusion and Restraint at a State Hospital,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:21Z,,0,0,09000064b91d3d6e
FDA-2025-P-4282-0159,FDA,FDA-2025-P-4282,Reference 14 - Dennis - Clozapine Therapy in a State Hospital,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:33Z,,0,0,09000064b91d3d72
FDA-2025-P-4282-0163,FDA,FDA-2025-P-4282,Reference 18 - Fazel Grann - The Population Impact of Severe Mental Illness on Violent Crime,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:46Z,,0,0,09000064b91d3d76
FDA-2025-P-4282-0168,FDA,FDA-2025-P-4282,Reference 23 - Gammon - Clozapine Why Is It So Uniquely Effective in the Treatment ofa Range of Neuropsychiatric Disorders,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:00Z,,0,0,09000064b91d3d7b
FDA-2025-P-4282-0182,FDA,FDA-2025-P-4282,Reference 37 - Wagner et al - Clozapine Optimization A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:42Z,,0,0,09000064b91d3d89
FDA-2025-P-4282-0152,FDA,FDA-2025-P-4282,Reference 8 - Clozapine Impact on Clinical Outcomes and Aggression in Severly Ill Adolescents with Childhood-Onset Schizophrenia,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:12Z,,0,0,09000064b91d3d6b
FDA-2025-P-4282-0171,FDA,FDA-2025-P-4282,Reference 26 - Kranzler - Clozapine Its Impact on Aggressive Behavior Among Children and Adolescents with Schizophrenia,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:08Z,,0,0,09000064b91d3d7e
FDA-2025-P-4282-0173,FDA,FDA-2025-P-4282,Reference 28 - Newman - Management of Aggression,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:13Z,,0,0,09000064b91d3d80
FDA-2025-P-4282-0175,FDA,FDA-2025-P-4282,Reference 30 - Potkin - Predicting Suicidal Risk in Schizophrenic and Schizoaffective Patients in a Prospective Two-Year Trial,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:19Z,,0,0,09000064b91d3d82
FDA-2025-P-4282-0179,FDA,FDA-2025-P-4282,Reference 34 - Shaheen - The Effect of Clozapine on Violence - Aggression in Adults with Mental Illness and Personality Disorders,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:33Z,,0,0,09000064b91d3d86
FDA-2025-P-4282-0181,FDA,FDA-2025-P-4282,Reference 36 - Volavka - Efficacy of Clozapine Olanzapine Risperidone and Haloperidol in Schizophrenia and Schizoaffective Disorder,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:39Z,,0,0,09000064b91d3d88
FDA-2025-P-4282-0146,FDA,FDA-2025-P-4282,Reference 2 - Barnes - Evidence-based Guidelines for the Pharmacological Treatment of Schizophrenia,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:42:51Z,,0,0,09000064b91d0f8e
FDA-2025-P-4282-0176,FDA,FDA-2025-P-4282,Reference 31 - Rabinowitz - Effect of clozapine on physical and verbal aggression,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:23Z,,0,0,09000064b91d3d83
FDA-2025-P-4282-0166,FDA,FDA-2025-P-4282,Reference 21 - Frogley - A systematic review of the evidence of clozapines anti-aggressive effects,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:54Z,,0,0,09000064b91d3d79
FDA-2025-P-4282-0180,FDA,FDA-2025-P-4282,Reference 35 - Volavka - Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:36Z,,0,0,09000064b91d3d87
FDA-2025-P-4282-0177,FDA,FDA-2025-P-4282,Reference 32 - Reid - Internet Archive Interlibrary Loan Fulfillment,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:27Z,,0,0,09000064b91d3d84
FDA-2025-P-4282-0149,FDA,FDA-2025-P-4282,Reference 5 - Buchanan - The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:01Z,,0,0,09000064b91d0f91
FDA-2025-P-4282-0153,FDA,FDA-2025-P-4282,Reference 8a - Chengappa - Clozapine Its impact on Aggressive Behavior Among Patients in a State Psychiatric Hospital,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:15Z,,0,0,09000064b91d3d6c
FDA-2025-P-4282-0157,FDA,FDA-2025-P-4282,Reference 12 - Citrome - Effects of Clozapine Olanzapine Risperidone and Haloperidol on Hostility Among Patients with Schizophrenia,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:27Z,,0,0,09000064b91d3d70
FDA-2025-P-4282-0161,FDA,FDA-2025-P-4282,Reference 16 - Ebrahim - Patient Response to Clozapine in a Forensic Psychiatric Hospital,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:41Z,,0,0,09000064b91d3d74
FDA-2025-P-4282-0165,FDA,FDA-2025-P-4282,Reference 20 - Fazel et al - Violent crime suicide and premature mortality in patients with schizophrenia and related disorders,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:51Z,,0,0,09000064b91d3d78
FDA-2025-P-4282-0170,FDA,FDA-2025-P-4282,Reference 25 - Keepers - The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:05Z,,0,0,09000064b91d3d7d
FDA-2025-P-4282-0174,FDA,FDA-2025-P-4282,Reference 29 - Nolan - Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and Schizoaffective Disorder,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:44:16Z,,0,0,09000064b91d3d81
FDA-2025-P-4282-0145,FDA,FDA-2025-P-4282,Reference 1 - Balbuena - Does Clozapine Promote Employability and Reduce Offending Among Mentally Disordered Offenders,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:42:48Z,,0,0,09000064b91d0f8d
FDA-2025-P-4282-0147,FDA,FDA-2025-P-4282,Reference 3 - Bhavsar - Clozapine Treatment and Offending A Within-Subject Study of Patients With Psychotic Disorders in Sweden,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:42:54Z,,0,0,09000064b91d0f8f
FDA-2025-P-4282-0162,FDA,FDA-2025-P-4282,Reference 17 - Faden - A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder,Supporting & Related Material,Background Material,2026-02-24T05:00:00Z,2026,2,,,2026-02-25T02:43:43Z,,0,0,09000064b91d3d75
FDA-2025-P-4282-0001,FDA,FDA-2025-P-4282,Citizen Petition from Gilbert Honigfeld,Other,Citizen Petition,2025-09-25T04:00:00Z,2025,9,2025-09-25T04:00:00Z,,2026-01-10T13:14:10Z,,1,0,09000064b8fdcd91
FDA-2025-P-4282-0002,FDA,FDA-2025-P-4282,Acknowledgement Letter from FDA DMB to Gilbert Honigfeld,Other,Acknowledgement Letter/Receipt,2025-09-25T04:00:00Z,2025,9,2025-09-25T04:00:00Z,,2025-09-25T19:20:21Z,,0,0,09000064b8fdcda7